Efficacy of faecal microbiota transplantation for patients with [IBS] in a randomised, double-blind, placebo-controlled study, 2019, El-Salhy et al

Andy · Jan 4, 2020

Objective Faecal microbiota transplantation (FMT) from healthy donors to patients with irritable bowel syndrome (IBS) has been attempted in two previous double-blind, placebo-controlled studies. While one of those studies found improvement of the IBS symptoms, the other found no effect. The present study was conducted to clarify these contradictory findings.

Design This randomised, double-blind, placebo-controlled study randomised 165 patients with IBS to placebo (own faeces), 30 g FMT or 60 g FMT at a ratio of 1:1:1. The material for FMT was obtained from one healthy, well-characterised donor, frozen and administered via gastroscope. The primary outcome was a reduction in the IBS symptoms at 3 months after FMT (response). A response was defined as a decrease of 50 or more points in the total IBS symptom score. The secondary outcome was a reduction in the dysbiosis index (DI) and a change in the intestinal bacterial profile, analysed by 16S rRNA gene sequencing, at 1 month following FMT.

Results Responses occurred in 23.6%, 76.9% (p<0.0001) and 89.1% (p<00.0001) of the patients who received placebo, 30 g FMT and 60 g FMT, respectively. These were accompanied by significant improvements in fatigue and the quality of life in patients who received FMT. The intestinal bacterial profiles changed also significantly in the groups received FMT. The FMT adverse events were mild self-limiting gastrointestinal symptoms.

Conclusions FMT is an effective treatment for patients with IBS. Utilising a well-defined donor with a normal DI and favourable specific microbial signature is essential for successful FMT. The response to FMT increases with the dose.
Click to expand...

Open access, https://gut.bmj.com/content/early/2019/12/18/gutjnl-2019-319630.full

Solstice · Jan 4, 2020

Isn't Lipkin or someone working with Lipkin working on mapping the microbiota to such an extent that it would be possible to tweak FMT to give just the right amount and sort of bacteria a patient would need for M.E.?

Solstice · Jan 4, 2020

https://www.healthrising.org/blog/2019/04/15/nih-chronic-fatigue-lipkin-davis-prusty-oh/

The NIH ME/CFS Conference II: Lipkin’s Possibilities, Prusty’s Big Idea, Oh’s Search and Ron Davis on ALWAYS Moving Forward by Cort Johnson.

Section about Dr Oh's talk:

Dr. Oh – The Strain of Getting Gut Results

Then it was on to Dr. Oh, who immediately shored up Lipkin’s gut findings with one of her own, indicating that butyrate bacteria are indeed reduced in ME/CFS. When she tried to add butyrate bacteria to ME/CFS cultures, they failed to thrive, suggesting that something in the teeming gut ecosystems of ME/CFS patients was knocking them out.
..

Oh said it’s entirely possible that researchers will be able to create a specialized fecal transplant, which, through a single or a few bacterial species, addresses the gut issues in ME/CFS. When that might occur, she would not say
…
Click to expand...

Pechius · Jan 4, 2020

23% vs 89%??

Wow. Some good shit they have there..

Log in or Sign up

Efficacy of faecal microbiota transplantation for patients with [IBS] in a randomised, double-blind, placebo-controlled study, 2019, El-Salhy et al

Andy Committee Member

Solstice Senior Member (Voting Rights)

Solstice Senior Member (Voting Rights)

Pechius Senior Member (Voting Rights)

Share This Page

Log in or Sign up

Efficacy of faecal microbiota transplantation for patients with [IBS] in a randomised, double-blind, placebo-controlled study, 2019, El-Salhy et al

Andy Committee Member

Solstice Senior Member (Voting Rights)

Solstice Senior Member (Voting Rights)

Pechius Senior Member (Voting Rights)

Share This Page

Useful Searches